logo
Big America hedge affects dollar's global standing

Big America hedge affects dollar's global standing

Axios27-06-2025
Some Wall Street veterans say appetite for the U.S. dollar is waning in ways not seen in years.
Why it matters: It could be the great unwind of the greenback binge of the past decade, when exposure to America was the world's safest — and a highly rewarding — investment. Now investors are hedging those bets.
What they're saying:"We're in a new era, where global investors no longer reflexively buy dollars or treasuries at the first sign of trouble," Jason Thomas, the head of global research and investment strategy at Carlyle, tells Axios.
Themos Fiotakis, a currency strategist at Barclays, puts it this way: "Since April, there's this trend that investors are trying to reduce the amount of dollar exposure. Some of that is a little bit of normalization, but there is a sense they need to go even deeper."
By the numbers: The U.S. dollar index is down more than 10% against a basket of other currencies this year, at a three-year low. The speed of the decline is the story.
The dollar index peaked when President Trump was inaugurated. But it has since "fallen farther, faster than in any year since the U.S. abandoned fixed exchange rates," Karl Schamotta, a currency strategist at payments firm Corpay, tells Axios.
The intrigue: The drop is among the hints of some "America-proofing" underway.
There was an exodus out of U.S. long-term bond funds in the second quarter, according to calculations by the Financial Times, the biggest flight since the pandemic onset, which signals less confidence in the nation's economic and fiscal fate.
Bearishness on the U.S. dollar hit a 20-year high among global fund managers in May, according to Bank of America.
More vendors want trade transactions denominated in local currencies, not the U.S. dollar, Paula Comings, head of currency sales at U.S. Bank, told Bloomberg, a sign that "could speak to the dollar's reputation."
The big picture: Among the investor turn-offs are Trump's volatile trade policy, stagflation fears, and exploding deficits.
Add to the list a Wall Street Journal report that Trump could announce a new Federal Reserve chair this summer, well before Jerome Powell's term ends next year.
If the pick is willing to push rates lower at Trump's whim, it would almost certainly strip America of its reputation as the global anchor of stability.
Off the fear list, though, is a proposal that could have constrained foreign investment, which Treasury Secretary Scott Bessent says he is aiming to remove from Trump's signature tax legislation.
Threat level: The global economy runs on the U.S. dollar, but the chaos and uncertainty is reviving questions about how long (or whether) the reign will continue.
"I have been getting a lot of inbound from clients about the euro as an alternative," Fiotakis says. While there is plenty of "anti-dollar" sentiment, no other currency has the might to replace it, he says.
"There is a sense of unease with how many dollars they have, but that is not something that is confirmed by anything besides the the price," he adds.
What to watch: Wall Street is still spooked by the immediate"Liberation Day" aftermath, which showed investors flee U.S. assets, selling government bonds and dollars.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

CNBC

time13 minutes ago

  • CNBC

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill. The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca's largest single manufacturing investment in the world and will "leverage AI, automation and data analytics to optimize production," the company said. The latest funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, and create "tens of thousands of jobs," AstraZeneca added. CEO Pascal Soriot said the commitment underpins the firm's "belief in America's innovation in biopharmaceuticals" and would support its ambition to reach $80 billion in annual revenue by 2030, half of which is expected to come from the U.S. AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The United States accounted for over 40% of the company's annual revenues in 2024. In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion U.S. investment. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets. AstraZeneca is the most valuable business listed on London's FTSE 100. The company declined to comment on the Times report. AstraZeneca's funding announcement follows similar moves by global pharmaceutical firms — including Novartis, Sanofi and Roche and U.S.-headquartered Eli Lilly and Johnson & Johnson — who have all vowed over recent months to ramp up their U.S. investment amid U.S. President Donald Trump's demands to reshore domestic manufacturing. The industry is awaiting further clarity on the Trump administration's pharma tariffs, with the final outcome of a Section 232 investigation into the sector due at the end of this month. An effort to rebalance U.S. drug prices with those paid by other countries is also underway. Trump earlier this month suggested that the industry could face levies of up to 200%, with a brief 12-18 month grace period to allow firms to relocate manufacturing stateside. However, many firms and analysts have dubbed the time frame as insufficient. "Typically for most medicines it's a three to four year horizon. We're working very hard to accelerate that as fast as we can and demonstrate we're making the investments we have planned," Novartis CEO Vas Narasimhan said last week during an earnings call, adding that he hoped the administration would make allowances.

Trump Truth Social: Trump Claims He Prevented Stock Market Crash in Swipe at Wall Street Journal
Trump Truth Social: Trump Claims He Prevented Stock Market Crash in Swipe at Wall Street Journal

Business Insider

timean hour ago

  • Business Insider

Trump Truth Social: Trump Claims He Prevented Stock Market Crash in Swipe at Wall Street Journal

Is there anything President Donald J Trump cannot do? Today on Truth Social he claimed that the U.S. stock market surge under his leadership – see chart below – had been driven by a number of complex financial, political and social factors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Okay, that's not true. Donald Factor In fact, President Trump said that the pick-up in share prices was down to just the one, crucial factor – President Trump. In a strange mixture of Trumpy Trump and Grumpy Trump this was the latest post picked up by our Trump Dashboard. 'The Wall Street Journal ran a typically untruthful story today by saying that Secretary of the Treasury, Scott Bessent, explained to me that firing Jerome 'Too Late' Powell, the Worst Federal Reserve Chairman in History, would be bad for the Market. Nobody had to explain that to me. I know better than anybody what's good for the Market, and what's good for the U.S.A. If it weren't for me, the Market wouldn't be at Record Highs right now, it probably would have CRASHED! So, get your information CORRECT. People don't explain to me, I explain to them!' If only the President had been around back in 1929, ensuring that the word did not fall into the Great Depression and the long, dark slide towards World War Two and all of its horrors. Confidence Returns But let's not be too cynical. Yes, a large reason behind the slump in April was down to fears over the President's tariff policies. His decision to pause or reduce some of the worst tariffs, as well as seal very favorable trade deals for the U.S. with the likes of the U.K. have also installed confidence. Better than expected economic and inflation data and positive corporate commentary have also helped. However, one analyst thinks that the rally – largely driven by U.S. tech may be running out of steam. Whenever a narrow rally losses steam, it usually signals that investors are starting to look for signs of a broader rally,' said Matt Maley, of Miller Tabak & Co. 'When they don't get it, they tend to pull back for a while.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store